| COVID-19 Clinical Research Studies | Lifetime | 145 | EG 1 | 99.19 |
| Long-Term Effects of COVID-19 | Lifetime | 103 | EG 1 | 98.79 |
| Essential Oils and Antimicrobial Activity | Lifetime | 193 | EG 4 | 99.02 |
| Natural Antidiabetic Agents Studies | Lifetime | 109 | EG 1 | 98.59 |
| Medicinal Plants and Neuroprotection | Lifetime | 98 | EG 3 | 97.46 |
| Phytochemical compounds biological activities | Lifetime | 871 | EG 3 | 88.99 |
| Pharmacological Effects of Medicinal Plants | Lifetime | 562 | EG 8 | 74.19 |
| Piperaceae Chemical and Biological Studies | Lifetime | 789 | EG 3 | 71.65 |
| Andrographolide Research and Applications | Lifetime | 639 | EG 2 | 49.71 |
| COVID-19 Clinical Research Studies | 2021-2025 | 4 | EG 1 | 99.93 |
| Long-Term Effects of COVID-19 | 2021-2025 | 13 | EG 1 | 99.71 |
| Essential Oils and Antimicrobial Activity | 2021-2025 | 8 | EG 1 | 99.58 |
| Natural Antidiabetic Agents Studies | 2021-2025 | 4 | EG 1 | 99.46 |
| Medicinal Plants and Neuroprotection | 2021-2025 | 6 | EG 2 | 98.63 |
| Phytochemistry and Biological Activities | 2021-2025 | 38 | EG 4 | 97.69 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 481 | EG 1 | 98.03 |
| Natural product bioactivities and synthesis | 2021-2025 | 71 | EG 5 | 95.86 |
| Drug-Induced Hepatotoxicity and Protection | 2021-2025 | 38 | EG 1 | 96.89 |
| Cholinesterase and Neurodegenerative Diseases | 2021-2025 | 52 | EG 1 | 95.65 |
| Pharmacological Receptor Mechanisms and Effects | 2021-2025 | 15 | EG 1 | 95.06 |
| Parkinson's Disease Mechanisms and Treatments | 2021-2025 | 204 | EG 1 | 97.29 |
| Phytochemicals and Antioxidant Activities | 2021-2025 | 295 | EG 4 | 96.62 |
| Phytochemical compounds biological activities | 2021-2025 | 25 | EG 1 | 93.77 |
| Peptidase Inhibition and Analysis | 2021-2025 | 222 | EG 1 | 95.21 |
| Adenosine and Purinergic Signaling | 2021-2025 | 52 | EG 1 | 93.26 |
| Inflammasome and immune disorders | 2021-2025 | 190 | EG 2 | 93.17 |
| Toxin Mechanisms and Immunotoxins | 2021-2025 | 46 | EG 3 | 90.68 |
| Traditional and Medicinal Uses of Annonaceae | 2021-2025 | 36 | EG 1 | 92.52 |
| Phytochemicals and Medicinal Plants | 2021-2025 | 72 | EG 1 | 89.42 |
| Ethnobotanical and Medicinal Plants Studies | 2021-2025 | 111 | EG 1 | 92.80 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 659 | EG 1 | 91.19 |
| Pharmacological Effects of Natural Compounds | 2021-2025 | 276 | EG 9 | 89.50 |
| Nuclear Receptors and Signaling | 2021-2025 | 59 | EG 2 | 88.21 |
| Computational Drug Discovery Methods | 2021-2025 | 782 | EG 16 | 92.39 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 337 | EG 2 | 90.51 |
| Alzheimer's disease research and treatments | 2021-2025 | 768 | EG 1 | 92.19 |
| Vitamin C and Antioxidants Research | 2021-2025 | 83 | EG 2 | 88.59 |
| Neuroprotection in Stroke and Neurodegeneration | 2021-2025 | 169 | EG 1 | 86.63 |
| Tryptophan and brain disorders | 2021-2025 | 768 | EG 2 | 88.68 |
| Pharmacological Effects of Medicinal Plants | 2021-2025 | 29 | EG 3 | 86.24 |
| Stress Responses and Cortisol | 2021-2025 | 561 | EG 1 | 87.83 |
| Kruppel-like factors research | 2021-2025 | 106 | EG 1 | 85.44 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 271 | EG 1 | 84.56 |
| Cancer Treatment and Pharmacology | 2021-2025 | 763 | EG 6 | 86.68 |
| COVID-19 Impact on Reproduction | 2021-2025 | 692 | EG 1 | 84.43 |
| Genomics, phytochemicals, and oxidative stress | 2021-2025 | 416 | EG 16 | 80.35 |
| GDF15 and Related Biomarkers | 2021-2025 | 168 | EG 1 | 75.90 |
| Erythrocyte Function and Pathophysiology | 2021-2025 | 490 | EG 1 | 78.63 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 270 | EG 1 | 77.46 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 694 | EG 1 | 76.92 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 526 | EG 6 | 77.30 |
| Berberine and alkaloids research | 2021-2025 | 138 | EG 3 | 75.57 |
| Andrographolide Research and Applications | 2021-2025 | 50 | EG 1 | 67.42 |
| Medicinal Plants and Bioactive Compounds | 2021-2025 | 174 | EG 6 | 71.54 |
| Vagus Nerve Stimulation Research | 2021-2025 | 351 | EG 1 | 72.45 |
| Phytochemistry Medicinal Plant Applications | 2021-2025 | 372 | EG 1 | 70.70 |
| Chemotherapy-induced organ toxicity mitigation | 2021-2025 | 201 | EG 44 | 70.48 |
| Moringa oleifera research and applications | 2021-2025 | 829 | EG 130 | 70.59 |
| Curcumin's Biomedical Applications | 2021-2025 | 560 | EG 16 | 68.53 |
| Neuropeptides and Animal Physiology | 2021-2025 | 874 | EG 2 | 68.97 |
| Blood properties and coagulation | 2021-2025 | 462 | EG 2 | 68.98 |
| Growth Hormone and Insulin-like Growth Factors | 2021-2025 | 959 | EG 1 | 69.83 |
| Nerve injury and regeneration | 2021-2025 | 921 | EG 3 | 67.49 |
| Sirtuins and Resveratrol in Medicine | 2021-2025 | 528 | EG 5 | 65.37 |
| Biochemical effects in animals | 2021-2025 | 936 | EG 11 | 67.69 |
| Antioxidant Activity and Oxidative Stress | 2021-2025 | 944 | EG 8 | 65.12 |
| Piperaceae Chemical and Biological Studies | 2021-2025 | 216 | EG 6 | 63.14 |
| Garlic and Onion Studies | 2021-2025 | 415 | EG 9 | 62.26 |
| Peroxisome Proliferator-Activated Receptors | 2021-2025 | 882 | EG 3 | 59.34 |
| Alkaloids: synthesis and pharmacology | 2021-2025 | 466 | EG 2 | 59.58 |
| Diverse Scientific Research Studies | 2021-2025 | 527 | EG 14 | 56.93 |
| Ginger and Zingiberaceae research | 2021-2025 | 599 | EG 16 | 57.19 |
| Plant-based Medicinal Research | 2021-2025 | 548 | EG 5 | 53.04 |
| Morinda citrifolia extract uses | 2021-2025 | 140 | EG 4 | 50.91 |
| Calcium signaling and nucleotide metabolism | 2021-2025 | 623 | EG 3 | 46.04 |
| Renin-Angiotensin System Studies | 2021-2025 | 659 | EG 6 | 41.24 |
| Enzyme function and inhibition | 2021-2025 | 837 | EG 47 | 37.80 |
